ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Pola Orbis fails to savor record profit as suspicion swirls

Tokyo-based cosmetics maker stalls in Asian markets as forgery rumors hound president

Pola Orbis' successful new anti-wrinkle cream helped draw 500 more people to its shareholders meeting March 27 than last year.

TOKYO -- Despite a record 2017 profit, Japanese cosmetics company Pola Orbis Holdings is being forced to walk a precarious path with shareholders as suspicion over a family inheritance gains new life and sales struggle in Asian markets.

The Pola Wrinkle Shot Serum facial treatment product has been a big hit among middle-aged and elderly women, driving the company's brisk earnings last year. President Satoshi Suzuki could have boasted about his decision to take a long view and spend 15 years to develop the product. Its first-year sales reached about 13 billion yen ($122 million).

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more